Literature DB >> 35717356

Tackling chronic kidney disease in diabetic patients with finerenone.

Bhaskar Das1, Ilse S Daehn2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35717356      PMCID： PMC9378607          DOI： 10.1016/j.tips.2022.05.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   17.638


× No keyword cloud information.
  10 in total

Review 1.  Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.

Authors:  Jonatan Barrera-Chimal; Sophie Girerd; Frederic Jaisser
Journal:  Kidney Int       Date:  2019-03-13       Impact factor: 10.612

2.  Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.

Authors:  Jana Grune; Niklas Beyhoff; Elia Smeir; Remigiusz Chudek; Annelie Blumrich; Zsofia Ban; Sarah Brix; Iris R Betz; Michael Schupp; Anna Foryst-Ludwig; Robert Klopfleisch; Philipp Stawowy; René Houtman; Peter Kolkhof; Ulrich Kintscher
Journal:  Hypertension       Date:  2018-02-05       Impact factor: 10.190

3.  Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.

Authors:  Larbi Amazit; Florian Le Billan; Peter Kolkhof; Khadija Lamribet; Say Viengchareun; Michel R Fay; Junaid A Khan; Alexander Hillisch; Marc Lombès; Marie-Edith Rafestin-Oblin; Jérôme Fagart
Journal:  J Biol Chem       Date:  2015-07-22       Impact factor: 5.157

4.  Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

Authors:  Bertram Pitt; Gerasimos Filippatos; Rajiv Agarwal; Stefan D Anker; George L Bakris; Peter Rossing; Amer Joseph; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Luis M Ruilope
Journal:  N Engl J Med       Date:  2021-08-28       Impact factor: 91.245

Review 5.  Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.

Authors:  Jonatan Barrera-Chimal; Ixchel Lima-Posada; George L Bakris; Frederic Jaisser
Journal:  Nat Rev Nephrol       Date:  2021-10-21       Impact factor: 28.314

6.  Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.

Authors:  Marianne Lachaux; Jonatan Barrera-Chimal; Lionel Nicol; Isabelle Rémy-Jouet; Sylvanie Renet; Anais Dumesnil; Didier Wecker; Vincent Richard; Peter Kolkhof; Frederic Jaisser; Antoine Ouvrard-Pascaud; Paul Mulder
Journal:  Diabetes Obes Metab       Date:  2018-06-27       Impact factor: 6.577

7.  Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.

Authors:  Lars Bärfacker; Alexander Kuhl; Alexander Hillisch; Rolf Grosser; Santiago Figueroa-Pérez; Heike Heckroth; Adam Nitsche; Jens-Kerim Ergüden; Heike Gielen-Haertwig; Karl-Heinz Schlemmer; Joachim Mittendorf; Holger Paulsen; Johannes Platzek; Peter Kolkhof
Journal:  ChemMedChem       Date:  2012-07-12       Impact factor: 3.466

8.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

9.  Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress.

Authors:  Raquel González-Blázquez; Beatriz Somoza; Marta Gil-Ortega; Miriam Martín Ramos; David Ramiro-Cortijo; Elena Vega-Martín; Angela Schulz; Luis Miguel Ruilope; Peter Kolkhof; Reinhold Kreutz; María S Fernández-Alfonso
Journal:  Front Pharmacol       Date:  2018-10-09       Impact factor: 5.810

10.  Enantioselective Total Synthesis of (-)-Finerenone Using Asymmetric Transfer Hydrogenation.

Authors:  Andreas Lerchen; Narasimhulu Gandhamsetty; Elliot H E Farrar; Nils Winter; Johannes Platzek; Matthew N Grayson; Varinder K Aggarwal
Journal:  Angew Chem Int Ed Engl       Date:  2020-11-23       Impact factor: 15.336
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.